Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q4 2021 · 10-K
Revenue$225.03M$225.03M−5.6% vs Q4 2020 Net Income-$11.04M-$11.04MN/M vs Q4 2020 EPS Diluted-$0.22-$0.22N/M vs Q4 2020 Gross Profit$81,807,000−28.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,547,000−96.7% Free Cash Flowderived-$10,085,000N/M Margins · derivedGross margin36.4%−11.3 pt vs Q4 2020
Operating margin-9.4%−20.3 pt vs Q4 2020
Net margin-4.9%−12.3 pt vs Q4 2020
ended Apr 3, 2021 · filed May 26, 2021 · 53 d after period end